Filing Details

Accession Number:
0001012975-16-001507
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-09-26 16:03:34
Reporting Period:
2016-09-22
Filing Date:
2016-09-26
Accepted Time:
2016-09-26 16:03:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1485003 Eleven Biotherapeutics Inc. EBIO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1222012 Noubar Afeyan 1 Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1255927 Jr M Edwin Kania 1 Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1503559 Flagship Ventures Fund Iv, L.p. 1 Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1508051 Flagship Ventures Fund Iv General Partner Llc 1 Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1508052 Flagship Ventures Fund 2007, L.p. 1 Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1508053 Flagship Ventures 2007 General Partner Llc 1 Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
1590973 Flagship Ventures Fund Iv-Rx, L.p. 1 Memorial Drive, 7Th Floor
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-09-22 112,731 $3.18 668,912 No 4 S Direct
Common Stock Disposition 2016-09-22 28,163 $3.18 167,288 No 4 S Direct
Common Stock Disposition 2016-09-22 188,367 $3.17 480,545 No 4 S Direct
Common Stock Disposition 2016-09-22 47,090 $3.17 120,198 No 4 S Direct
Common Stock Disposition 2016-09-23 12,482 $3.16 468,063 No 4 S Direct
Common Stock Disposition 2016-09-23 3,118 $3.16 117,080 No 4 S Direct
Common Stock Disposition 2016-09-23 41,178 $3.10 426,885 No 4 S Direct
Common Stock Disposition 2016-09-23 10,293 $3.10 106,787 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,833,802 Direct
Footnotes
  1. Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  2. Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  3. Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC. Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Each of the filing persons, other than Flagship 2007, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  4. The transactions were executed in multiple trades at prices ranging from $3.15 to $3.29. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
  5. The transactions were executed in multiple trades at prices ranging from $3.15 to $3.235. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
  6. The transactions were executed in multiple trades at prices ranging from $3.15 to $3.16. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
  7. The transactions were executed in multiple trades at prices ranging from $3.10 to $3.15. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.